Neuro3d Completes a EUR 31.5 Million Third Round Financing
The new funds will be used to continue the clinical development of the Company's broad pipeline of innovative drug candidates targeting psychiatric disorders, such as schizophrenia, depression and anxiety, as well as accelerate additional drug candidates into the clinic to broaden its late-stage pipeline with innovative drugs acting via new mechanism of actions. The Company's drug portfolio includes ocaperidone in Phase II trials for treatment of schizophrenia, two new antidepressants with different mechanism of actions in Phase I trials and several drug candidates in research or preclinical development.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.